Project Grant HT94252510589
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
The federal Project Grant award in the amount of $705,038.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund the "DEVELOPMENT OF GUAR-T AS A NOVEL CLASS OF UNIVERSAL CELLULAR IMMUNOTHERAPIES FOR OVARIAN CANCER" at Yale University over the period of July 1, 2025 to June 30, 2029. This research project aims to develop innovative cellular immunotherapies for the treatment of ovarian cancer, a...
This $1,004,472.00 Project Grant was awarded on June 15, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports Yale University in conducting advanced biomedical research on mast cell therapy for ovarian cancer. The research aims to transform healthcare for military service members and the broader public by developing innovative approaches to disease prevention, diagnosis, treatment, and management of...
This $1,005,000.00 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports research on mast cell therapy for ovarian cancer at Yale University. The award, with a period of performance from June 15, 2025 to June 14, 2029, will fund advanced biomedical research focused on transforming healthcare for military service members and the broader public. The grant supports Yale University's work in...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
The Defense Health Agency awarded Yale University a $3,129,087.00 Project Grant on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced research to develop integrative platforms for cellular immunotherapies against resistant hematopoietic malignancies and solid tumors. Key aims include targeting combinations of gene editing and CAT inhibition to enhance CAR-T cell function, and investigating gene editing coupled with CAT...
The Yale University was awarded a $753,749 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from March 2022 through March 2025 to target replication stress in triple-negative breast cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...
The Yale University was awarded a $1,244,745 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 to June 2025 to overcome resistance to EGFR inhibitors in advanced head and neck cancers. The Military Medical Research and Development program supports biomedical research to transform military and public health care through innovative solutions. This award will further...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
This federal Project Grant award of $1,009,054 from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) supports research to discover and therapeutically target endogenous retroviruses in clear cell renal cell carcinoma. The award recipient is Yale University, a private research university with expertise in medical research, healthcare, and technology development. The performance period is from September 1, 2025 to August 31, 2029. This grant is...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...